On October 22, 2026, the Stochastic Oscillator for AKTS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 50 instances where the indicator left the oversold zone. In 45 of the 50 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AKTS's RSI Oscillator exited the oversold zone, 22 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for AKTS just turned positive on October 21, 2026. Looking at past instances where AKTS's MACD turned positive, the stock continued to rise in 28 of 31 cases over the following month. The odds of a continued upward trend are 90%.
Following a +4.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTS advanced for three days, in 175 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AKTS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.923) is normal, around the industry mean (2.973). P/E Ratio (-12.676) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. AKTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CLRO saw its Momentum Indicator move below the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 85 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CLRO turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 34 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
CLRO moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CLRO moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CLRO entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLRO advanced for three days, in 172 of 211 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CLRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLRO's P/B Ratio (-13.482) is slightly lower than the industry average of (7.180). P/E Ratio (-0.176) is within average values for comparable stocks, (6.784). Projected Growth (PEG Ratio) (0.520) is also within normal values, averaging (0.778). CLRO has a moderately high Dividend Yield (1.042) as compared to the industry average of (0.131). P/S Ratio (0.533) is also within normal values, averaging (11.937).
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. CLRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
AKTS | CLRO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 97 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 68 | 100 | |
SMR RATING 1..100 | 94 | 100 | |
PRICE GROWTH RATING 1..100 | 80 | 96 | |
P/E GROWTH RATING 1..100 | 16 | 6 | |
SEASONALITY SCORE 1..100 | 19 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLRO's Valuation (3) in the Telecommunications Equipment industry is in the same range as AKTS (14). This means that CLRO’s stock grew similarly to AKTS’s over the last 12 months.
AKTS's Profit vs Risk Rating (68) in the Telecommunications Equipment industry is in the same range as CLRO (100). This means that AKTS’s stock grew similarly to CLRO’s over the last 12 months.
AKTS's SMR Rating (94) in the Telecommunications Equipment industry is in the same range as CLRO (100). This means that AKTS’s stock grew similarly to CLRO’s over the last 12 months.
AKTS's Price Growth Rating (80) in the Telecommunications Equipment industry is in the same range as CLRO (96). This means that AKTS’s stock grew similarly to CLRO’s over the last 12 months.
CLRO's P/E Growth Rating (6) in the Telecommunications Equipment industry is in the same range as AKTS (16). This means that CLRO’s stock grew similarly to AKTS’s over the last 12 months.
| AKTS | CLRO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 76% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Momentum ODDS (%) | N/A | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Advances ODDS (%) | 1 day ago 84% | 16 days ago 82% |
| Declines ODDS (%) | 7 days ago 90% | 4 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 77% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AKTS’s FA Score shows that 2 FA rating(s) are green while CLRO’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AKTS’s TA Score shows that 4 TA indicator(s) are bullish while CLRO’s TA Score has 4 bullish TA indicator(s).
AKTS (@Biotechnology) experienced а -0.42% price change this week, while CLRO (@Telecommunications Equipment) price change was -43.13% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
The average weekly price growth across all stocks in the @Telecommunications Equipment industry was -6.40%. For the same industry, the average monthly price growth was -14.55%, and the average quarterly price growth was -17.22%.
AKTS is expected to report earnings on Nov 12, 2026.
CLRO is expected to report earnings on Nov 13, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Telecommunications Equipment (-6.40% weekly)The Telecommunications Equipment industry produces voice and data communications equipment, which includes fiber optic delivery products, digital signal processors, high-speed voice, data and video delivery. Additionally, satellite systems, global positioning systems, wireless data systems, personal communications equipment, telephone handsets and payload equipment for satellites also fall into this category. Apple Inc., QUALCOMM Incorporated and Nokia are major global players in this segment.
A.I.dvisor tells us that AKTS and SPRY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKTS and SPRY's prices will move in lockstep.
| Ticker / NAME | Correlation To AKTS | 1D Price Change % | ||
|---|---|---|---|---|
| AKTS | 100% | +2.07% | ||
| SPRY - AKTS | 29% Poorly correlated | +3.35% | ||
| CRDO - AKTS | 24% Poorly correlated | -10.70% | ||
| KN - AKTS | 24% Poorly correlated | -4.41% | ||
| LITE - AKTS | 24% Poorly correlated | -11.54% | ||
| ZBRA - AKTS | 23% Poorly correlated | -1.75% | ||
More | ||||
A.I.dvisor tells us that CLRO and AKTS have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRO and AKTS's prices will move in lockstep.
| Ticker / NAME | Correlation To CLRO | 1D Price Change % | ||
|---|---|---|---|---|
| CLRO | 100% | +7.87% | ||
| AKTS - CLRO | 21% Poorly correlated | +2.07% | ||
| SONM - CLRO | 20% Poorly correlated | -0.79% | ||
| SYNX - CLRO | 20% Poorly correlated | +0.07% | ||
| AIOT - CLRO | 20% Poorly correlated | +1.16% | ||
| VSAT - CLRO | 15% Poorly correlated | -5.74% | ||
More | ||||